Scarica l'app Stockscreener
5.05
1.00%
0.05
Precedente Chiudi:
$5.00
Aprire:
$5.05
Volume 24 ore:
722.60K
Relative Volume:
1.05
Capitalizzazione di mercato:
$410.96M
Reddito:
$70.14M
Utile/perdita netta:
$-76.24M
Rapporto P/E:
-4.5495
EPS:
-1.11
Flusso di cassa netto:
$-57.06M
1 W Prestazione:
+11.48%
1M Prestazione:
-4.36%
6M Prestazione:
+42.25%
1 anno Prestazione:
+87.73%
Intervallo 1D:
$5.015
$5.43
Intervallo di 1 settimana:
$4.63
$5.43
Portata 52W:
$2.53
$6.08
Codexis Inc Stock (CDXS) Company Profile
Nome
Codexis Inc
Settore
Industria
Telefono
650-421-8100
Indirizzo
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
Confronta CDXS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
5.05 | 410.96M | 70.14M | -76.24M | -57.06M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-19 | Downgrade | The Benchmark Company | Buy → Hold |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-05-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-02-29 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-11-07 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-08-07 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-05-09 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Ripresa | Piper Sandler | Overweight |
| 2022-03-02 | Ripresa | Cowen | Outperform |
| 2021-04-12 | Iniziato | Piper Sandler | Overweight |
| 2021-03-01 | Iniziato | Stifel | Buy |
| 2021-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-10 | Iniziato | The Benchmark Company | Buy |
| 2019-01-17 | Aggiornamento | First Analysis Sec | Neutral → Outperform |
| 2018-05-16 | Iniziato | Stephens | Overweight |
| 2017-10-13 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-31 | Iniziato | Jefferies | Buy |
| 2017-01-26 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2017-01-04 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2016-01-06 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Codexis Inc Borsa (CDXS) Ultime notizie
Codexis expands board with new director Christos Richards - MSN
Codexis, Inc. (NASDAQ:CDXS) Sees Significant Increase in Short Interest - MarketBeat
Codexis expands board with new director Christos Richards By Investing.com - Investing.com Australia
Tallon Kerry Patrick Purchases New Position in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Barclays PLC Purchases 70,255 Shares of Codexis, Inc. (NASDAQ:CDXS) - Defense World
Barclays PLC Has $640,000 Stock Holdings in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Codexis appoints new independent director By Investing.com - Investing.com Australia
Codexis, Inc. Appoints Christos Richards to Board of Directors -January 16, 2025 at 04:05 pm EST - Marketscreener.com
Codexis appoints new independent director - Investing.com India
Codexis Appoints Christos Richards to Board of Directors - TipRanks
Codexis Strengthens Board with Life Sciences Veteran Christos Richards, Expert in 450+ Executive Placements - StockTitan
Jane Street Group LLC Reduces Stock Holdings in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Codexis (NASDAQ:CDXS) Stock Price Crosses Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Codexis (NASDAQ:CDXS) Stock Crosses Above Two Hundred Day Moving Average – What’s Next? - Defense World
Synthetic DNA Market Set to Witness Stunning Growth by 2024 Ti - openPR
Codexis Announces New Employment Inducement Grants - GlobeNewswire
Codexis Awards Strategic Equity Grants to New Employees Under 2024 Inducement Plan - StockTitan
Is There An Opportunity With Codexis, Inc.'s (NASDAQ:CDXS) 22% Undervaluation? - Yahoo Finance
Codexis sees $210,994 stock purchase by Opaleye management - Investing.com Nigeria
Geode Capital Management LLC Boosts Stake in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Caribou Biosciences Strengthens Leadership Team with Veteran Biotech CFO Sri Ryali - StockTitan
Codexis sees $210,994 stock purchase by Opaleye management By Investing.com - Investing.com South Africa
Codexis, Inc. (NASDAQ:CDXS) Short Interest Up 10.5% in December - MarketBeat
State Street Corp Acquires 41,480 Shares of Codexis, Inc. (NASDAQ:CDXS) - Defense World
Stifel Financial Corp Lowers Stock Holdings in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Stifel Financial Corp Has $530,000 Position in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
BNP Paribas Financial Markets Trims Position in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Codexis (NASDAQ:CDXS) Stock Price Crosses Above 200-Day Moving AverageHere's Why - MarketBeat
Codexis's SWOT analysis: enzymatic pioneer's stock poised for RNAi revolution - Investing.com India
Codexis's SWOT analysis: enzymatic pioneer's stock poised for RNAi revolution By Investing.com - Investing.com South Africa
Codexis, Inc.'s (NASDAQ:CDXS) high institutional ownership speaks for itself as stock continues to impress, up 17% over last week - Yahoo Finance
Is Codexis (NASDAQ:CDXS) Using Debt In A Risky Way? - Simply Wall St
Jacobs Levy Equity Management Inc. Decreases Stock Holdings in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Codexis Awards Strategic Equity Package: 208K Shares in Options and RSUs for Key New Hires - StockTitan
Codexis stock soars to 52-week high, touches $4.92 By Investing.com - Investing.com Canada
Codexis stock soars to 52-week high, touches $4.92 - Investing.com India
Global Artificial Sweeteners Market to Observe Growth at a CAGR of ~4% by 2030 | DelveInsight - GlobeNewswire Inc.
Codexis, Inc. (NASDAQ:CDXS) Shares Sold by Fred Alger Management LLC - MarketBeat
Codexis, Inc. (NASDAQ:CDXS) Sees Large Decrease in Short Interest - MarketBeat
Cantor Fitzgerald Reaffirms “Overweight” Rating for Codexis (NASDAQ:CDXS) - Defense World
Codexis's SWOT analysis: enzymatic platform poised to shake up RNAi stock - Investing.com
Codexis (NASDAQ:CDXS) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Codexis Inc Azioni (CDXS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):